MedTrace Logo

MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors

NCT06030869 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-09-11

No results posted yet for this study

Summary

The MyCustom study is a investigator initiated trial(IIT), prospective real-world clinical research project, a genetic biomarker-driven "basket" (tissue-type agonistic) study. The target population covers a variety of solid advanced malignant tumors, including but not limited to patients with small cell lung, gastric, prostate, bladder cancer, head and neck squamous carcinoma or lacking effective treatment after standard treatment failure.

Conditions

  • Refractory Solid Tumors
  • Next Generation Sequencing

Sponsors & Collaborators

  • Tianjin Medical University Second Hospital

    lead OTHER

Principal Investigators

  • Haitao Wang, Ph.D · Tianjin Medical University Second Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2023-12-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06030869 on ClinicalTrials.gov